ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Q4 2025 Earnings Call Transcript
Acadia Pharmaceuticals (ACAD) Q4 Earnings Top Estimates
Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.17 per share a year ago.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU
ACAD expects a negative CHMP opinion on trofinetide marketing application for Rett syndrome, likely delaying a potential EU approval.
Why Acadia (ACAD) is Poised to Beat Earnings Estimates Again
Acadia (ACAD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why Acadia Pharmaceuticals (ACAD) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Acadia (ACAD) Up 22.6% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality
Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID's patent protection now extends to 2030, supporting >10% Y/Y revenue growth and providing a stable revenue base. DAYBUE missed launch expectations but remains a durable rare-disease asset; ex-U.S. growth is likely to be modest.
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
